Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies

Tumor lysis syndrome (TLS) is a commonly observed oncological emergency that requires prompt diagnosis and treatment. Rasburicase is a recombinant urate oxidase endorsed in TLS for the treatment of hyperuricemia. The effect of single-dose 7.5 mg rasburicase at longer follow-ups was not widely invest...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2022-02, Vol.22 (2), p.e71-e76
Hauptverfasser:	Yaman, Samet, Başcı, Semih, Turan, Gökhan, Ulu, Bahar Uncu, Yiğenoğlu, Tuğçe Nur, Dal, Mehmet Sinan, Kızıl Çakar, Merih, Altuntaş, Fevzi
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute kidney injury Hematologic Neoplasms - complications Hematologic Neoplasms - drug therapy Hematological cancer Humans Hyperuricemia Hyperuricemia - drug therapy Hyperuricemia - etiology TLS Tumor Lysis Syndrome - diagnosis Tumor Lysis Syndrome - drug therapy Tumor Lysis Syndrome - etiology Urate Oxidase - therapeutic use Uric acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Tumor lysis syndrome (TLS) is a commonly observed oncological emergency that requires prompt diagnosis and treatment. Rasburicase is a recombinant urate oxidase endorsed in TLS for the treatment of hyperuricemia. The effect of single-dose 7.5 mg rasburicase at longer follow-ups was not widely investigated. Eighty-two patients included in the study with clinical TLS and laboratory TLS. The primary endpoint was the normalization of uric acid (
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2021.08.009